小白菊提取物 小白菊内酯

中文名称:

小白菊内酯

中文同义词:

小白菊内酯(试剂级对照品);欧苷菊;银胶菊内酯;小白菊内酯, 来源于小白菊花;小白菊内酯(药典标准品);小白菊内酯;小白菊提取物|小白菊内酯;PARTHENOLIDE 小白菊内酯

英文名称:

Parthenolide

英文同义词:

Parthenolide, Tanacetum parthenium - CAS 20554-84-1 - Calbiochem;Factory Price Parthenolide 20554-84-1;Natural Plant Extracts Parthenolide 20554-84-1 High Purity HPLC>98%;Feverfew P.E Parthenlide;[1aR-(1aR*,4E,7aS*,10aS*,-10bR*)]-2,3-6,7,7a,8,10a,10b-Octahydro-1a,5-dimethyl-8-methyleneoxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one;(1aR,4E,7aS,10aS,10bS)-2,3,6,7,7a,8,10a,10b-Octahydro-1a,5-dimethyl-8-methyleneoxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one;4,5α-Epoxy-6β-hydroxygermacra-1(10),11(13)-dien-12-oic acid γ-lactone;4,5alpha-epoxy-6beta-hydroxy-germacra-1(10),11(13)-dien-12-oic acid gamma-lactone

CAS号:

20554-84-1

分子式:

C15H20O3

分子量:

248.32

EINECS号:

692-532-0

相关类别:

分析标准品;中药对照品;标准品;中药标准品;医药原料;植物提取物;对照品;主打产品-主打产品;优势产品;其他生化试剂;分析对照品;标准提取物;其他原料;标准品-中药标准品;标准品 -中药标准品;倍半萜;标准提取物;分析试剂标准品;Sesqui-Terpenoids;Isoprenoid/terpenoidNeurotransmitters;Anti-Proliferative AgentsNutrition Research;Antitumor Agents;Biochemicals Found in Plants;Cancer Research;Others;Serotonergics;Prostanoid receptor and related;Natural Product;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;inhibitor

Mol文件:

20554-84-1.mol

熔点 

115-116 °C (lit.)

比旋光度 

D20 -81.4° (c = 1.04 in chloroform); D22 -71.4° (c = 0.220 in CH2Cl2)

沸点 

394.1±42.0 °C(Predicted)

密度 

1.13±0.1 g/cm3(Predicted)

储存条件 

2-8°C

形态

White solid

Merck 

14,7048

CAS 数据库

20554-84-1

应用

倍半萜内酯类化合物小白菊内酯是从小白菊中提取的化合物，最初被用来治疗皮肤感染、风湿病以及偏头痛。近期研究表明，小白菊内酯可抑制前列腺癌、乳腺癌、胃癌、白血病癌、肾癌、肺癌、结肠腺癌、成神经管细胞瘤等癌细胞的生长，在动物模型上小白菊内酯还能治疗紫外线引起的皮肤癌。对其作用机理研究发现，小白菊内酯能抑制转录因子NF-κB的激活，其活性可能主要来源于p65/NF-κB亚基的Cys38上的巯基与含笑内酯发生了 Michael加成反应，由于NF-κB是调控肿瘤侵袭、转移、药物抗性的重要基因，抑制NF-κB的激活有可能提高肿瘤对于抑瘤剂所引起的细胞凋亡的敏感性。最近，纽约罗切斯特大学医学院的Jordan，C.T.博士及其同事发现小白菊内酯能够在基本不损伤正常干细胞的情况下，针对性地消灭引发急性和慢性骨髓性白血病的干细胞，从而有可能根本上遏制白血病复发，小白菊内酯这一独特的作用机制，已引起人们的广泛关注。

生物活性

(-)-Parthenolide, Nuclear Factor-κB抑制剂，可特异性地耗尽HDAC1蛋白，而不影响其他I/II类 HDACs。促进MDM2的泛素化并激活p53的细胞功能。

靶点

Target Value HDAC1 NF-κB MDM2 ubiquitination p53 ()

Target

Value

HDAC1

NF-κB

MDM2 ubiquitination

p53 ()

体外研究

Parthenolide (PTL) has a dose-dependent growth inhibition effect on NSCLC cells Calu-1, H1792, A549, H1299, H157, and H460. Parthenolide can induce cleavage of apoptotic proteins such as CASP8, CASP9, CASP3 and PARP1 both in concentration- and time-dependent manner in tested lung cancer cells, indicating that apoptosis is trigged after Parthenolide exposure. In addition to induction of apoptosis, Parthenolide also induces G 0 /G 1 cell cycle arrest in a concentration-dependent manner in A549 cells and G 2 /M cell cycle arrest in H1792 cells.

体内研究

Only Parthenolide, the HDAC inhibitor with anti-inflammatory features, displayed a potent anti-apoptotic effect in Phb1 KO hepatocytes. Indeed, TSA and Parthenolide-treated hepatocytes showed increased levels of FXR, and reduced levels of CYP7A1, HDAC4, TNFα, TRAIL and Bax suggesting a less toxic effect of bile acids as a results of specific HDAC inhibition, resulting in the attenuation of the Phb1 KO hepatocytes apoptotic response. Importantly, Parthenolide exerts a protective effect from the liver injury after BDL in Phb1 KO mice. Indeed, Parthenolide treatment results in a reduction of the mortality rate of this mice after BDL associated with a lower apoptotic response as revealed by a reduction of necrotic areas, Tunel-staining, as well as decreased ALT (8431±957 vs.4225±210 U/L) and AST (4805±300 vs.2242±438 U/L) activities compared to control Phb1 KO mice.

危险品标志 

Xi,C,F

危险类别码 

11-34

安全说明 

22-24/25-45-36/37/39-26-16

WGK Germany 

3

RTECS号

LY4220000

海关编码 

29322090